The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

ClinicalDrugs & Targets

FDA approves treatment to reduce risk of breast cancer returning

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

FDA approved Nerlynx (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer. For patients with this type of cancer, Nerlynx is the first extended adjuvant therapy, a form of therapy that is taken after an initial treatment to further lower the risk of the cancer coming back. Nerlynx is indicated for adult patients who have been previously treated with a regimen that includes the drug trastuzumab.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Pfizer seeks to improve breast cancer outcomes in Sub-Saharan Africa
With help from Conquer Cancer’s EveryGrant and ASCO’s Sub-Saharan Africa Regional Council, Pfizer awards grants to seven countries

Pfizer External Research & Grants’ “Improving Breast Cancer Quality of Care via Meaningful Capacity Building in Sub-Saharan Africa,” powered by EveryGrant, has announced grants totaling more than $900,000 for addressing inequities and improving the quality of breast cancer care in Sub-Saharan Africa.
By Claire Marie Porter
ClinicalTrials & Tribulations

The other side of the patient portal: Reflections from a cancer center leader

It started innocuously enough. I looked in the mirror and noticed a pigmented area on my scalp just into the hairline. Like many patients, thoughts started running through my head: “Maybe it’s nothing.” Looking at my Outlook calendar, it was packed morning-to-night with meetings, patients, and travel, so I decided I would get that spot checked out the minute I had “time.” 
By Ruben A. Mesa
Cancer Policy

A farewell post by an unidentified NCI employee triggers an accusation of “undermining the Trump administration”

In the morning of May 28, presumably before turning off the lights and closing the office door, someone at the now defunct NCI Office of Communications and Public Liaision decided to post a farewell message to the cancer community.  The message, posted on multiple social media accounts, read: We’re taking a pause here - but...

By Jacquelyn Cobb
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account